A tool for selecting patients with a high probability of sustained virological response to peginterferon alfa-2a (40kD)/ribavirin

  • Peter Ferenci, Rodrigo Aires, Ioan Ancuta, Andrew Arohnson, Hugo Cheinquer, Dragan Delic, Michael Gschwantler, Dominique Larrey, Ludovico Tallarico, Manuela Schmitz, Fernando Tatsch, Denis Ouzan
  • Liver International, January 2014, Wiley
  • DOI: 10.1111/liv.12439

The authors haven't finished explaining this publication. If you are the author, sign in to claim or explain your work.

Read Publication


The following have contributed to this page: Peter Ferenci